Pharmacogenomics: History, Development and Challenges


  • Aditi Ranade Ms



Pharmacogenomics, Adverse drug reactions, Drug Development, Personalized Medicine, Pharmacogenomic Testing


Pharmacogenomics is seen as the combination of pharmacology and genomics. It studies the effect of genetic variations and genetic polymorphisms on the drug response. Individuals respond differently to drugs and sometimes the effects are unpredictable. Differences in DNA that alter the function or expression of proteins that are targeted by drugs can contribute notably to variation in the responses of individuals. This intersection of genomics and medicine has the capacity to yield a new set of molecular diagnostic tools which can be used to optimize drug therapy. By optimizing drug therapy, reducing adverse drug reaction events, and developing patient-centric approaches, pharmacogenomics can achieve the goal of personalized medicine wherein the right drug or right amount of drug is given to the right patient. The present article sheds light upon the historical perspective of pharmacogenomics and the seminal studies examining the fact that patients do not uniformly respond to medications. It also emphasizes the current status of pharmacogenomics and drug development. Some of the barriers in implementing pharmacogenomics have also been presented. 


Nebert DW, Zhang G. 16 - Pharmacogenomics. In: Pyeritz RE, Korf BR, Grody WW, editors. Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics [Seventh Edition] [Internet]. Academic Press; 2019 [cited 2021 Dec 14]. p. 445–86. Available from:

Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol. 2001 Oct;52[4]:345–7.

Somogy A. Evolution of pharmacogenomics. Proc West Pharmacol Soc. 2008;51:1–4.

Alomar MJ. Factors affecting the development of adverse drug reactions [Review article]. Saudi Pharm J SPJ. 2014 Apr;22[2]:83–94.

Marchant B. Pharmacokinetic factors influencing variability in human drug response. Scand J Rheumatol Suppl. 1981;39:5–14.

Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: The genetics of variable drug responses. Circulation. 2011 Apr 19;123[15]:1661–70.

Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019 May;12[5]:407–42.

Kalow W. Human pharmacogenomics: The development of a science. Hum Genomics. 2004 Aug 1;1[5]:375.

O’Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol. 2006 Jun;61[6]:783–6.

Zhang W, Ratain MJ, Dolan ME. The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinforma Biol Insights. 2008 Feb 1;2:15–23.

Gupta PD. Pharmacogenetics, Pharmacogenomics and Ayurgenomics for Personalized Medicine: A Paradigm Shift. Indian J Pharm Sci. 2015;77[2]:135–41.

Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014 Feb;171[3]:580–94.

Ahmed S, Zhou Z, Zhou J, Chen S-Q. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics. 2016 Oct;14[5]:298–313.

Pharmacogenomics: The Right Drug to the Right Person [Internet]. [cited 2021 Dec 14]. Available from:

Ross S, Anand SS, Joseph P, Paré G. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis. 2012 Apr 5;1[1]:cvd.2012.012001.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations | Pharmacogenomics [Internet]. [cited 2021 Dec 14]. Available from:

Dean L. Clopidogrel Therapy and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Medical Genetics Summaries [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2012 [cited 2021 Dec 14]. Available from:

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J-S, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 [CYP2C19] Genotype and Clopidogrel Therapy. Clin Pharmacol Ther. 2011 Aug;90[2]:328–32.

Research C for DE and. Table of Pharmacogenomic Biomarkers in Drug Labeling. FDA [Internet]. 2021 Aug 18 [cited 2021 Dec 14]; Available from:

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics Pers Med. 2014;7:227–40.

Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013 May;14[7]:835–43.

Davies P. Favism. Postgrad Med J. 1961 Aug 1;37[430]:477–80.

Meletis J. Favism.A brief history from the “abstain from beans” of Pythagoras to the present. Arch Hell Med. 2012 Apr 1;29:258–63.

Sinha M, Kalim M, Khan A, Siddiqui H, Sayeed U, Wadhwa D, et al. PHARMACOGENOMICS: A STEP AHEAD IN MODERN DAY DRUG DISCOVERY. Int J Adv Eng Sci Res. 2014 Dec 10;1:13–26.

Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008 Jan 1;111[1]:16–24.

Kiani F, Schwarzl S, Fischer S, Efferth T. Three-Dimensional Modeling of Glucose-6-phosphate Dehydrogenase-Deficient Variants from German Ancestry. PLoS ONE. 2007 Jul 18;2[7]:e625.

Carson PE et al [1956] Enzymatic defi ciency in primaquine-sensitive erythrocytes. Science 124[3220]:484–485.

Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957 Oct 19;165[7]:835–7.

Cecchin E, Stocco G. Pharmacogenomics and Personalized Medicine. Genes. 2020 Jun;11[6]:679.

Kalow W. Pharmacogenomics: historical perspective and current status. Methods Mol Biol Clifton NJ. 2005;311:3–15.

Kraft JC, Kim J, Schwinn DA, Landau R. A History of Pharmacogenomics Related to Anesthesiology. In: Eger II EI, Saidman LJ, Westhorpe RN, editors. The Wondrous Story of Anesthesia [Internet]. New York, NY: Springer; 2014 [cited 2021 Dec 15]. p. 585–96. Available from:

Kalow W.Pharmacogenetics: Heredity and the Response to Drugs. W.B.Saunders, Philadelphia, PA: London, 1962.

Pharmacogenomics: bench to bedside | Nature Reviews Drug Discovery [Internet]. [cited 2021 Dec 15]. Available from:

Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 2005 Mar 7;581[1–2]:97–104.

Sim E, Abuhammad A, Ryan A. Arylamine N-acetyltransferases: From Drug Metabolism and Pharmacogenetics to Drug Discovery. Br J Pharmacol. 2014 Jan 28;171.

Pharmacogenetics of the arylamine N-acetyltransferases | The Pharmacogenomics Journal [Internet]. [cited 2021 Dec 15]. Available from:

Gonzalez FJ et al [1988] Characterization of the common genetic defect in humans defi - cient in debrisoquine metabolism. Nature 331[6155]:442–446.

Eichelbaum M et al [1979] Defective N-oxidation of sparteine in man: a new phar_macogenetic defect. Eur J Clin Pharmacol 16[3]:183–187.

Gonzalez FJ, Skoda RC, Kimura S,et al.Characterizationof the common genetic-defect in humans.

Skoda, R. C., Gonzalez, F. J., Demierre, A. & Meyer, U.A. Two mutant alleles of the human cytochrome P-450db1 gene [P450C2D1] associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl Acad. Sci. USA,1988: 85: 5240– 5243.

Distlerath, L. M. et al. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two International Journal of Advances in Engineering & Scientific Research, Volume 1, Issue 8, Dec-2014, pp 13-26.

CHANG K-L, WEITZEL K, SCHMIDT S. Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. Am Fam Physician. 2015 Oct 1;92[7]:588–94.

Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett. 1992 Dec;64-65 Spec No:115–22.

Snyder LH [1932] Studies in human inheri_tance. IX. The inheritance of taste defi ciency in man. Ohio J Sci 32:436–468.

Kim UK et al [2003] Positional cloning of the human quantitative trait locus underlying taste sensitivity to phenylthiocarbamide. Science 299[5610]:1221–1225.

Harris HW et al [1958] Comparison of iso_niazid concentrations in the blood of people of Japanese and European descent; therapeu_tic and genetic implications. Am Rev Tuberc 78[6]:944–948.

Evans DA et al [1960] Genetic control of iso_niazid metabolism in man. Br Med J 2[5197]:485–4.

Aklillu, E. et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 1996: 278: 441–446.

Hong-Guang Xie & Felix W Frueh Pharmacogenomics step towards personalized medicines future Medicine .2005: 325-337.

Weinshilboum RM, Sladek SL [1980] Mercaptopurine pharmacogenetics: mono_genic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32[5]:651–662.

Kalow W [1956] Familial incidence of low pseudocholinesterase level. Lancet 271: 576–577.

Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358[6]:568–79.

Van Den Driessche G, Fourches D. Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study. J Cheminformatics. 2017 Mar 4;9:13.

Dean L. Abacavir Therapy and HLA-B*57:01 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Medical Genetics Summaries [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2012 [cited 2021 Dec 15]. Available from:

Dean L. Irinotecan Therapy and UGT1A1 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Medical Genetics Summaries [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2012 [cited 2021 Dec 15]. Available from:

Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer. 2009 Sep 1;115[17]:3858–67.

. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 [2001].

Eisenhauer, E. A. From the molecule to the clinic — inhibiting HER2 to treat breast cancer. N. Engl. J. Med. 344, 841–842 [2001].

Dean L, Kane M. Mercaptopurine Therapy and TPMT and NUDT15 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Medical Genetics Summaries [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2012 [cited 2021 Dec 15]. Available from:

Kumar V, Majumdar D. Pharmacogenomics – The New Trend for Personalized Medicine ARTICLE INFO. Indian J Pharm Biol Res. 2016 Jan 1;4:39–49.

Crews KR, Hicks JK, Pui C-H, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther. 2012 Oct;92[4]:467–75.

Becquemont L [June 2009]. “Pharmacogenomics of adverse drug reactions: practical applications and perspectives”. Pharmacogenomics. 10 [6]: 961–9. doi:10.2217/pgs.09.37. PMID 19530963.

Kuznetsov V, Lee HK, Maurer-Stroh S, et al. How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst 2013; 1: 2.

Surendiran A, Pradhan SC, Adithan C. Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol. 2008 Aug;40[4]:137–43.

. Luo Y, Zhao X, Zhou J, et al. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun 2017; 8: 573.

Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discovery. Pharmacol Rev 2014; 66: 334-395.

Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep 2004; 5: 837-842.

Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013 Jul;14[9]:1085–97.

Oates J, Lopez D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. Int J Biomed Investig. 2018;1[2]:111.

Cully M. Target validation: Genetic information adds supporting weight. Nat Rev Drug Discov 2015; 14: 525.

Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol 2011; 162: 1239-1249.

Thomsen SK, Gloyn AL. Human genetics as a model for target validation: finding new therapies for diabetes. Diabetologia 2017; 60: 960-970.

Mestan KK, Ilkhanoff L, Mouli S, et al. Genomic sequencing in clinical trials. J Transl Med 2011; 9: 222.

Curtin F, Schulz P. Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence. Dialogues Clin Neurosci. 2011 Jun;13[2]:183–90.

Akhoon N. Precision Medicine: A New Paradigm in Therapeutics. Int J Prev Med. 2021 Feb 24;12:12.

Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011;13: 987-995.

Research C for DE and. Pharmacogenomic Data Submissions [Internet]. U.S. Food and Drug Administration. FDA; 2020 [cited 2021 Dec 17]. Available from:

Wang B, Canestaro WJ, Choudhry NK. Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels. JAMA Intern Med. 2014 Dec 1;174[12]:1938–44.


Chadwell K: Clinical practice on the horizon: personalized medicine. Clin Nurse Spec 2013; 27:36– 43.

Dean L. Warfarin Therapy and VKORC1 and CYP Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Medical Genetics Summaries [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2012 [cited 2021 Dec 17]. Available from:

Fung E, Patsopoulos NA, Belknap SM, O’Rourke DJ, Robb JF, Anderson JL, et al. Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Semin Thromb Hemost. 2012 Nov;38[8]:893–904.


Gage BF, Lesko LJ. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008;25:45-51.

Abraham BK, Adithan C. Genetic polymorphism of CYP2D6. Indian J Pharmacol 2001;33:147-69.

Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-865.

Chang MT, McCarthy JJ, Shin J. Clinical application of pharmacogenetics: focusing on practical issues. Pharmacogenomics 2015; 16: 1733-1741.

McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007; 3: 751-759.

McPherson E. Genetic diagnosis and testing in clinical practice. Clin Med Res 2006; 4: 123-129.

Klein ME, Parvez MM, Shin JG. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. J Pharm Sci 2017; 106: 2368-2379.

Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics 1999; 56: 247- 258.

Malsagova KA, Butkova TV, Kopylov AT, Izotov AA, Potoldykova NV, Enikeev DV, et al. Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. Pharmaceutics. 2020 Dec 19;12[12]:1240.

RPRD Diagnostics Partners with St. Jude Children’s Research Hospital to Offer Comprehensive Pharmacogenetics Testing [2017] In. RPRD Diagnostics, CISION PR Newswire.

Arwood MJ, Chumnumwat S, Cavallari LH, et al. Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. Clin Transl Sci 2016; 9: 233-245.

Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev. 2009 May;30[2]:55–65.

Daly A. Pharmacogenetics: A general review on progress to date. Br Med Bull. 2017 Oct 11;124:1–15.

Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, et al. Pharmacogenomics: Challenges and Opportunities. Ann Intern Med. 2006 Nov 21;145[10]:749–57.

Cardon LR, Harris T. Precision medicine, genomics and drug discovery. Hum Mol Genet 2016;25:R166–72.

Kroese M, Zimmern RL, Sanderson S. Genetic tests and their evaluation: Can we answer the key questions? Genetics in Medicine 2004; 6: 475-480.

Ikediobi ON, Shin J, Nussbaum RL, et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther 2009; 86: 28-31.

Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011 Mar;89[3]:464–7.

Bertier G, Carrot-Zhang J, Ragoussis V, et al. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. Genome Med 2016; 8: 108.

Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharmgenomics Pers Med 2015; 8: 99-110.

Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement Pharmacogenetic Knowledge for Precision Medicine. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2016 Dec 1;73[23]:1977–85.

Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011 Mar;89[3]:464–7.

Caudle KE, Klein TE, Hoffman JM, Müller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium [CPIC] Guideline Development Process. Curr Drug Metab. 2014 Feb;15[2]:209–17.

Barbarino JM, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB: A worldwide resource for pharmacogenomic information. WIREs Syst Biol Med. 2018;10[4]:e1417.

Clinical Pharmacogenetics Implementation Consortium [Internet]. [cited 2021 Dec 18]. Available from:

Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice [Internet]. [cited 2021 Dec 18]. Available from:

Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 2020 Jun;146[6]:1395–404.

Fig. 6.2 The current challenges and barriers to clinical implementation... [Internet]. ResearchGate. [cited 2021 Dec 18]. Available from:

Challenges in pharmacogenomics research [Internet]. ResearchGate. [cited 2021 Dec 18]. Available from:

Salari P, Larijani B. Ethical Issues Surrounding Personalized Medicine: A Literature Review. Acta Med Iran. 2017 Mar;55[3]:209–17.

Ethical perspectives on pharmacogenomic profiling in the drug development process | Nature Reviews Drug Discovery [Internet]. [cited 2021 Dec 18]. Available from:

Emerging Ethical Issues in Pharmacogenomics | SpringerLink [Internet]. [cited 2021 Dec 18]. Available from:

Ethical and legal implications of pharmacogenomics | Nature Reviews Genetics [Internet]. [cited 2021 Dec 18. Available from:


How to Cite

Ranade, A. (2021). Pharmacogenomics: History, Development and Challenges. International Journal of Advances in Scientific Research and Engineering (IJASRE), ISSN:2454-8006, DOI: 10.31695/IJASRE, 7(12), 26–37.